Current trials
Card Grid - Our clinical trials
This phase III, open-label, multi-centre randomised clinical trial aims to determine whether groin ultrasound monitoring is a safe and effective replacement for invasive groin lymph node dissection in the management of early-stage vulvar cancer.
EN.10 tests de-escalated adjuvant treatment in patients with p53 wildtype/NSMP early-stage endometrial cancer.
A Phase III randomised clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer.
Researchers will use blood and tissue samples collected as part of the feMMe trial, to identify whether an endometrial cancer patient will or will not benefit from an LNG-IUD, in place of a hysterectomy.
This clinical trial will evaluate the effectiveness and safety of Dostarlimab, an immunotherapy drug for patients with early-stage endometrial cancer as an alternate, non surgical treatment option.
The NODE study is a randomised feasibility trial comparing groin ultrasound surveillance with groin node surgery in Australian women with vulvar cancer, aiming to reduce the extent of surgery for this condition and improve patient recovery.
Study 1 aims to assess whether non-invasive groin ultrasound is a feasible and accurate method of predicting groin node involvement in vulvar cancer patients.
Study 2 aims to evaluate the utility of blood biomarkers in the differential diagnosis of vulvar intraepithelial neoplasia versus invasive vulvar cancer.
Study 2 aims to evaluate the utility of blood biomarkers in the differential diagnosis of vulvar intraepithelial neoplasia versus invasive vulvar cancer.
This study focuses on women at high risk of ovarian cancer and whether an alternative surgical approach is equivalent to the standard method in preventing ovarian cancer for women without the associated symptoms and risks.